

**AMENDMENT TO**  
**RULES COMMITTEE PRINT 118-36**  
**OFFERED BY MR. KILDEE OF MICHIGAN**

On page 762, after line 25, insert the following:

1 **SEC. 17\_\_ . PFAS HEALTH EFFECTS ASSESSMENT, REC-**  
2 **COMMENDATIONS, AND GUIDANCE.**

3 (a) PERIODIC ASSESSMENT AND RECOMMENDA-  
4 TIONS.—

5 (1) AGREEMENT.—The Director of the Agency  
6 for Toxic Substances and Disease Registry (in this  
7 section referred to as the “Director”) shall enter  
8 into an agreement with the National Academies of  
9 Sciences, Engineering, and Medicine (or another ap-  
10 propriate entity if the National Academies declines  
11 to enter into such agreement) under which the Na-  
12 tional Academies or the other appropriate entity  
13 agrees—

14 (A) to assess the health effects of per- and  
15 polyfluoroalkyl substances (in this section re-  
16 ferred to as “PFAS”) that can be measured in  
17 human tissues;

18 (B) to formulate clinical recommendations  
19 on addressing such health effects;

1 (C) not later than 2 years after the date  
2 of entry into such agreement, to complete the  
3 initial assessment under subparagraph (A) and  
4 formulate the initial recommendations under  
5 subparagraph (B); and

6 (D) to update the most recent assessment  
7 and recommendations under this paragraph—

8 (i) every 5 years; or

9 (ii) more frequently as determined  
10 necessary by the Director based on an as-  
11 sessment of the science.

12 (2) TIMING OF ENTRY INTO AGREEMENT.—The  
13 Director shall enter into the agreement required by  
14 paragraph (1) not later than 60 days after the date  
15 of enactment of this Act.

16 (b) UP-TO-DATE GUIDANCE.—Based on the results  
17 of the most recent assessment and recommendations  
18 under subsection (a), the Director, in consultation with  
19 the entity with which the Director enters into the agree-  
20 ment under subsection (a), shall—

21 (1) not later than 5 years after the date of  
22 entry into the agreement required by subsection  
23 (a)—

24 (A) issue up-to-date clinical guidance on  
25 addressing the health effects of PFAS;

1 (B) post such guidance on the public  
2 website of the Agency for Toxic Substances and  
3 Disease Registry; and

4 (C) disseminate such guidance to State  
5 and local public health authorities and appro-  
6 priate health care professionals; and

7 (2) every 5 years thereafter, or more frequently  
8 as determined necessary by the Director based on an  
9 assessment of the science, issue, post, and dissemi-  
10 nate up-to-date guidance as described in paragraph  
11 (1).

